Novavax COVID-19 vaccine Nuvaxovid received EUA in Taiwan for use in individuals aged 18 and over
On Jun. 23 2022, Novavax announced that the Taiwan Food and Drug Administration had granted emergency use authorization…
Innovation Pharmaceuticals reported Brilacidin inhibited Omicron, Delta, Gamma and Alpha SARS-CoV-2 variants
On Jun. 23, 2022, Innovation Pharmaceuticals reported that Brilacidin, the Company’s defensin-mimetic drug candidate exhibiting broad-spectrum antiviral activity,…
U.S. FDA approved Merck’s VAXNEUVANCE for prevention of invasive pneumococcal disease in infants and children
On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…
Benaroya Research Institute received $11.4 million to explore link between viruses and immune system diseases
On Jun. 17, 2022, Benaroya Research Institute at Virginia Mason (BRI) announced a 5-year, $11.4 million grant from…
Oragenics announced publication of positive data for NT-CoV2-1 intranasal COVID-19 vaccine candidate in Scientific Reports
On Jun. 14 2022, Oragenics announced the publication of an article co-authored by Oragenics and collaborators at Inspirevax…
Pfizer reported additional data on PAXLOVID supporting New Drug Application submission to U.S. FDA
On Jun. 14 2022, Pfizer reported data from the Phase 2/3 EPIC-SR (Evaluation of Protease Inhibition for COVID-19…
Novavax COVID-19 vaccine Nuvaxovid provisionally registered in Australia as booster in individuals aged 18 and over
On Jun. 13 2022, Novavax announced that the Australian Therapeutic Goods Administration (TGA) has granted provisional registration of…
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
Merck and Ridgeback announcd data for investigational LAGEVRIO (molnupiravir) from Phase 3 MOVe-OUT study
On Jun. 7, 2022, Merck and Ridgeback Biotherapeutics announced the Annals of Internal Medicine had published additional data…
Pfizer announced investment $120 million to produce COVID-19 oral treatment in the U.S.
On Jun. 6, 2022, Pfizer further strengthened its commitment to United States manufacturing with a $120 million investment…
Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
Biotechnology | Disease | Medicine | NIH | Therapeutics
NIH study confirmed benefit of supplements for slowing age-related macular degeneration
On Jun. 2, 2022, the National Institutes of Health reported that the Age-Related Eye Disease Studies (AREDS and…
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
Wake Forest CCSG cut from 5 years to 3 as center changes leadership, administrative structure
May 27, 2022, the National Cancer Institute (NCI) truncated the just-renewed five-year Cancer Center Support Grant held by…
IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and IAVI announced that the first participant screenings are soon to start for…
Tabula Sapiens multiple-organ, single-cell transcriptomic atlas of humans published
On May 13, 2022, the Tabula Sapiens Consortium announced it had published a molecular reference atlas for more…
KPWHRI report supported value of COVID-19 drugs
On May 11, 2022, Kaiser Permanente Washington Health Research Institute reported that new treatments for people at high…
Novavax submitted variations to expand Australian and New Zealand provisional approval of Nuvaxovid COVID-19 vaccine in Great Britain
On May 6, 2022, Novavax announced the submission of variations to the Australian Therapeutic Goods Agency (TGA) and…
Novavax’s COVID-19 vaccine Nuvaxovid arrived in Singapore
On May 6, 2022, Novavax announced that deliveries of it’s COVID-19 vaccine continued around the world and the…
Sorrento announced full enrollment of phase I study of intranasal STI-9199 (COVISHIELD) against Omicron BA.2 and all variants of concern
On May 2, 2022, Sorrento announced its Phase I study of intranasal STI-9199 (COVISHIELDTM) had been fully enrolled…
Biotechnology | COVID-19 | FDA | Life Science News | Vaccine
Pfizer and BioNTech submitted application for U.S. EUA for COVID-19 vaccine booster dose in children 5 through 11 years of age
On Apr. 26, 2022, Pfizer and BioNTech submitted an application to the U.S. Food and Drug Administration (FDA)…
Cocrystal Pharma collaborated with the NIAID to evaluate COVID-19 protease inhibitors
On Apr. 21, 2022, Cocrystal Pharma announced a Non-Clinical Evaluation Agreement with the National Institute of Allergy and…
Novavax announced approval of Nuvaxovid COVID-19 vaccine for primary and booster immunization in Japan
On Apr. 19, 2022, Novavax announced that its partner, Takeda, received manufacturing and marketing approval from the Japan…
Swissmedic granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Apr. 13, 2022, Novavax announced that Swissmedic had granted Novavax conditional marketing authorization (CMA) for Nuvaxovid COVID-19…
Biotechnology | Diagnostics | Life Science News | Non-Profit Research | Oncology | Radiology | Therapeutics | Women's Health
Fred Hutch and Seattle Cancer Care Alliance unite, reshaped relationship with UW Medicine
On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
Merck and Ridgeback reported data demonstrating treatment with LAGEVRIO (molnupiravir) associated with more rapid elimination of SARS-CoV-2 than placebo
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…
Sorrento reported FDA clearance for phase 2/3 study for Abivertinib in treatment of pospitalized patients with severe pneumonia due to COVID-19
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
Lucira’s COVID-19 & flu at-home molecular test showed Positive clinical trial results
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
Pfizer and BioNTech received expanded U.S. EUA for additional COVID-19 vaccine booster in individuals Aged 50 Years and older
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
US Food and Drug Administration revised EUA for sotrovimab due to Omicron BA.2 subvariant
On Mar. 25, 2022, GlaxoSmithKline and Vir Biotechnology announced that the US Food and Drug Administration had amended…